Literature DB >> 12387843

Challenges of PK/PD measurements in modern drug development.

P Workman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12387843     DOI： 10.1016/s0959-8049(02)00395-7

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  14 in total

Review 1.  Envisioning the future of early anticancer drug development.

Authors:  Timothy A Yap; Shahneen K Sandhu; Paul Workman; Johann S de Bono
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

Review 2.  Appraising iniparib, the PARP inhibitor that never was--what must we learn?

Authors:  Joaquin Mateo; Michael Ong; David S P Tan; Michael A Gonzalez; Johann S de Bono
Journal:  Nat Rev Clin Oncol       Date:  2013-10-15       Impact factor: 66.675

3.  Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.

Authors:  Jian-Feng Lu; Erik Rasmussen; Beth Y Karlan; Ignace B Vergote; Lynn Navale; Mita Kuchimanchi; Rebeca Melara; Daniel E Stepan; David M Weinreich; Yu-Nien Sun
Journal:  Cancer Chemother Pharmacol       Date:  2012-01-01       Impact factor: 3.333

4.  Future directions in the evaluation of c-MET-driven malignancies.

Authors:  Johann S de Bono; Timothy A Yap
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

5.  Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.

Authors:  Timothy A Yap; Mike I Walton; Lisa-Jane K Hunter; Melanie Valenti; Alexis de Haven Brandon; Paul D Eve; Ruth Ruddle; Simon P Heaton; Alan Henley; Lisa Pickard; Gowri Vijayaraghavan; John J Caldwell; Neil T Thompson; Wynne Aherne; Florence I Raynaud; Suzanne A Eccles; Paul Workman; Ian Collins; Michelle D Garrett
Journal:  Mol Cancer Ther       Date:  2010-12-29       Impact factor: 6.261

6.  Quantitative analysis of ATM phosphorylation in lymphocytes.

Authors:  Christopher J Bakkenist; R Kenneth Czambel; Yan Lin; Nathan A Yates; Xuemei Zeng; Jeffery Shogan; John C Schmitz
Journal:  DNA Repair (Amst)       Date:  2019-06-04

7.  Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts.

Authors:  Yuen-Li Chung; Helen Troy; Rebecca Kristeleit; Wynne Aherne; L Elizabeth Jackson; Peter Atadja; John R Griffiths; Ian R Judson; Paul Workman; Martin O Leach; Mounia Beloueche-Babari
Journal:  Neoplasia       Date:  2008-04       Impact factor: 5.715

8.  A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.

Authors:  Simon Pacey; Richard H Wilson; Mike Walton; Martin M Eatock; Anthea Hardcastle; Anna Zetterlund; Hendrik-Tobias Arkenau; Javier Moreno-Farre; Udai Banerji; Belle Roels; Heidi Peachey; Wynne Aherne; Johan S de Bono; Florence Raynaud; Paul Workman; Ian Judson
Journal:  Clin Cancer Res       Date:  2011-01-28       Impact factor: 12.531

9.  The stem cell factor antibody enhances the chemotherapeutic effect of adriamycin on chemoresistant breast cancer cells.

Authors:  Neil D Jelly; Issam I Hussain; Jennifer Eremin; Oleg Eremin; Mohamed El-Sheemy
Journal:  Cancer Cell Int       Date:  2012-05-29       Impact factor: 5.722

Review 10.  Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials.

Authors:  Joo Ern Ang; Stan Kaye; Udai Banerji
Journal:  Curr Drug Targets       Date:  2012-11       Impact factor: 3.465
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.